Condition: HER2 Expressing Solid Tumors · Sponsor: Vironexis Biotherapeutics Inc.
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
This description comes directly from the study's public registry record.
Allen Reha · 908-938-6019 · allen.reha@vironexis.com
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| SCRI Denver DDU at HealthOne | Denver, Colorado, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Hackensack Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| VCU Massey CTO Phase I Solid Team | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07192432